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Abstract
An outbreak of post-acupuncture cutaneous infections due to Mycobacterium abscessus occurred in Ansan, Korea, from November 2007
through to May 2008. During this time a prospective, observational, non-randomized study was conducted involving 52 patients that
were diagnosed with cutaneous M. abscessus infection. We compared the clinical response between patients treated with clarithromycin
plus amikacin regimen and those treated with clarithromycin plus moxiﬂoxacin regimens with regard to time to resolution of the cuta-
neous lesions. Among the 52 study patients, 33 were treated with clarithromycin plus amikacin, and 19 were treated with clarithromy-
cin plus moxiﬂoxacin. The baseline characteristics for the treatment groups were not signiﬁcantly different, except for initial surgical
excision (n = 27 vs. 6, respectively, p = 0.001). The median time (weeks) to resolution of the lesions in the clarithromycin plus moxi-
ﬂoxacin-treated subjects was signiﬁcantly shorter than that in the clarithromycin plus amikacin-treated subjects (17 ± 1.1 vs. 20 ± 0.9,
respectively, p = 0.017). With adjustments for age, location of lesions, prior incision and drainage, and excision during medical therapy,
clarithromycin plus moxiﬂoxacin-treated subjects were more likely to have resolved lesions (hazard ratio, 0.387; 95% conﬁdence inter-
val, 0.165–0.907; p = 0.029). The frequency of drug-related adverse events in the two treatment groups was not signiﬁcantly different
(n = 18 vs. 14, respectively; p = 0.240). The most common adverse event was gastrointestinal discomfort. The results of our study
showed that the combination regimen of clarithromycin and moxiﬂoxacin resulted in a better clinical response than a regimen of clari-
thromycin plus amikacin when used for treatment of cutaneous M. abscessus infection.
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Introduction
Mycobacterium abscessus is a rapidly growing non-tuberculous
mycobacterium that is ubiquitously present in water, and is
commonly associated with soft tissue infections [1,2]. Soft
tissue infections associated with M. abscessus are typically
caused by trauma and surgical or other procedures, including
acupuncture, liposuction and subcutaneous injections [3–7].
Emerging infections associated with M. abscessus are increas-
ingly important, especially because of their relationships with
nosocomial infections and their tendency to disseminate in
immunocompromised hosts [8–10]. Although the features of
soft tissue infections caused by M. abscessus have been
described previously [2,11], the optimal treatment for these
infections has not been established. Current recommended
therapy includes drainage of the abscess and a prolonged
course of combination antimicrobial therapy, speciﬁcally clari-
thromycin or azithromycin combined with at least one addi-
tional drug [2,3,7,12]. M. abscessus typically exhibits in vitro
susceptibility to amikacin, cefoxitin and clarithromycin
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[13–16], and various regimens such as oral clarithromycin
plus cefoxitin or amikacin injection are effective [5,7]. How-
ever, such treatment regimens are expensive, nephrotoxic,
ototoxic, and are given by injection, which is undesirable for
many patients. Newer potential oral agents being considered
for use in combination with clarithromycin include the 8-
methoxyﬂuoroquinolones (gatiﬂoxacin and moxiﬂoxacin)
[17]. However, their role in the treatment of M. abscessus
infections remains to be determined.
There was an outbreak of post-acupuncture cutaneous
infections due to M. abscessus in Korea, from November
2007 through to May 2008 [18].The aim of this study was to
compare the efﬁcacy of clarithromycin plus amikacin and
clarithromycin plus moxiﬂoxacin as combination therapies
for cutaneous infections due to M. abscessus. To our knowl-
edge, this is the ﬁrst clinical study to evaluate the efﬁcacy of




We performed a prospective observational study of 52
patients with cutaneous M. abscessus infection who were
referred to our hospital after the outbreak of post-acupunc-
ture cutaneous infections. A conﬁrmed case was deﬁned as a
patient with isolation of M. abscessus from the cutaneous
lesions. A clinical case was deﬁned as a patient who was diag-
nosed post-acupuncture with a cutaneous infection related to
the outbreak without microbiological conﬁrmation.
Patients were treated with two treatment protocols
depending on the patient’s choice and the investigator’s rec-
ommendation with regard to the accessibility of the injection
site. The ﬁrst regimen was a combination of clarithromycin
(CLR) and amikacin (AMK). The second regimen was a com-
bination of CLR and moxiﬂoxacin (MXF). The CLR dose was
500 mg daily in two divided doses given orally until the cuta-
neous lesions resolved. Either AMK (250 mg intramuscularly,
three times a week) or MXF (400 mg once-daily dose given
orally) was combined with CLR for the initial 4 weeks.
Follow-up during treatment was performed once every
2 weeks for the initial 2 months and then once a month. We
examined patients for cutaneous lesions, questioned patients
regarding drug-related adverse events and performed labora-
tory tests at each visit. The clinical response was assessed
based on the improvement in clinical symptoms and mea-
surement of the size and number of cutaneous lesions at
each visit. A patient’s treatment was considered to have
failed if the lesions persisted with no apparent change, the
lesions progressed, or if new lesions appeared after the initial
4 weeks of treatment. A follow-up evaluation was conducted
2 months after the completion of treatment.
Resolution of the cutaneous lesions was deﬁned as the
absence of symptoms, a decrease of more than 50% in the
subcutaneous nodules, and the absence of new lesions at
2 months after treatment completion. The efﬁcacy of each
treatment was assessed based on the duration of medical
treatment needed at the end of therapy.
This study was approved by the hospital institutional
review board committee. Written informed consent was
obtained from the enrolled patients.
Laboratory testing
Cultures and acid-fast stain. Specimens for culture were
obtained by needle aspiration, swabbing of local drainage or
biopsy, depending on the character of the lesion. Samples
were stained for acid-fast bacilli by the Ziehl-Neelsen
method and plated onto Ogawa medium. Positive cultures
were referred to the National Tuberculosis Institute for
identiﬁcation of the Mycobacterium species.
Antimicrobial susceptibility tests. Antimicrobial susceptibility
testing for M. abscessus isolates was performed at the
National Institute of Health, Korea Centers for Disease Con-
trol and Prevention (KCDC), according to the guidelines of
Clinical and Laboratory Standards Institutes (CLSI) [19,20]
[19,20]. All isolates were tested against amikacin, tobramycin,
cefoxitin, clarithromycin, ciproﬂoxacin, gatiﬂoxacin, levoﬂoxa-
cin, moxiﬂoxacin, doxycycline, sulfamethoxazole, linezolid
and imipenem by the broth microdilution system using Mul-
ler-Hinton broth [21]. Staphylococcus aureus ATCC29213 was
used as a control strain for the determination of the minimal
inhibitory concentration (MIC) test. MICs of all tested drugs
were interpreted according to the guidelines described by
CLSI criteria [19]. The breakpoints of moxiﬂoxacin, gatiﬂoxa-
cin and levoﬂoxacin, for M. abscessus, have not yet been
described by the CLSI.
Pulsed-ﬁeld gel electrophoresis (PFGE). At the KCDC labora-
tory, molecular characterization was performed by PFGE,
using previously described techniques [22,23] and the restric-
tion enzyme Ase I (Promega, Madison, WI, USA). PFGE was
performed for 19 h at 14C at 6.0 V/cm with a pulse time of
2.9–35.4 s with a CHEF DR III apparatus (Bio-Rad Laborato-
ries, Richmond, CA, USA).
Statistical analysis
Data analysis was performed using the software SPSS 13.0
(SPSS Inc., Chicago, IL, USA). The association between cate-
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gorical variables was examined with the chi-square test. Con-
tinuous variables were analysed by the t-test. Using the Kap-
lan–Meier method, we estimated the resolution time curves
for cutaneous lesions treated by the CLR + AMK regimen as
well as the CLR + MXF regimen. For univariate analysis, the
log-rank test was used to compare resolution times between
the CLR + AMK regimen and the CLR + MXF regimen, and
Cox’s proportional hazard model was applied to adjust
demographic information and infection-related factors such
as age, the location of lesions, prior incision and drainage,
and excision during medical therapy. Patients who were
switched to a different treatment regimen were censored at
the time of the switch.
Results
Study population
During the outbreak, 52 patients were enrolled in the study.
Among them, 16 (30.8%) were microbiologically conﬁrmed
and 36 (69.2%) were clinical cases. Fig. 1 shows an overview
of the antimicrobial therapy in the 52 study patients. Among
the 33 patients who were started on the CLR + AMK regi-
men, six (18.2%) discontinued the regimen within 4 weeks of
therapy because of poor compliance or noncompliance.
Among the 19 patients who were initially treated with the
CLR + MXF regimen, six (31.6%) discontinued the treatment
by 4 weeks because of poor compliance or noncompliance,
as well as adverse drug-related events. Eight of the 27
patients who received the CLR + AMK regimen showed no
improvement in the cutaneous lesions, and their regimen
was changed to the CLR + MXF after 4 weeks.
The baseline characteristics of the two treatment groups
at the times of enrollment and follow up are shown in
Table 1. The majority of patients were female in both
groups. The most common location of the lesions in both
groups was the trunk (48.5% vs. 52.6%). Compared with the
patients who received the CLR + AMK regimen, patients
who received the CLR + MXF regimen had signiﬁcantly
more cutaneous lesions in the lower extremities. Patients
who received the CLR + AMK treatment had experienced
signiﬁcantly more prior treatments, including incision and
drainage of cutaneous lesions, before the study, compared
with the patients treated with the CLR + MXF regimen. This
difference was mainly due to the late approval of the
CLR + MXF regimen by the institutional review board com-
mittee. The patients with persistent infection after incision
and drainage at local clinics were enrolled relatively early in
this study and were all allocated to the CLR + AMK group,
the only treatment regimen available at the time.
Other characteristics were not signiﬁcantly different
between the groups, including age, co-morbidity, number of
lesions, and purulent discharge from the lesions. During the
follow-up period, the frequency of change in the antimicro-
bial regimens within 4 weeks was not signiﬁcantly different
between the two groups.
Antimicrobial susceptibility
Antimicrobial susceptibility testing was performed in 12 of the
16 conﬁrmed cases. Results of the MICs and susceptibility
FIG. 1.Overview of antimicrobial ther-
apy in 52 study patients with cutaneous
M. abscessus infection. CLR, clarithromy-
cin; AMK, amikacin; MXF, moxiﬂoxacin.
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testing are presented in Table 2. CLR and AMK were active
against all isolates tested. Eleven (91.7%) of the isolates were
resistant to or had an intermediate response to ciproﬂoxacin.
The ranges of MICs for moxiﬂoxacin, gatiﬂoxacin and levoﬂox-
acin were 1–8, 2–8 and 4–8 lg/mL, respectively.
PFGE results
All 12 isolates of M. abscessus in this study yielded indistin-
guishable PFGE proﬁles by Ase I digestion (Fig. 2). This sug-
gested that they were from a single or closely related clone.
Treatment outcomes
The clinical response was evaluated in all patients enrolled,
except for two patients in the CLR + AMK group who were
lost to follow up. Fig. 3 shows a comparison of the clinical
responses in both treatment groups with regard to the time
to resolution of the cutaneous lesions. Patients who were
initially treated with the CLR + MXF regimen showed signiﬁ-
cantly more rapid resolution of the cutaneous lesions, com-
pared with patients treated with the CLR + AMK regimen
(median time to the resolution, 17 ± 1.1 vs. 20 ± 0.9 weeks;
p = 0.017). Similarly, after adjustment for age, location of
lesions, prior incision and drainage, and excision during medi-
cal therapy, patients who were treated with CLR + MXF
were more likely to have resolution of their cutaneous
lesions (hazard ratio, 0.387; 95% conﬁdence interval,
0.165–0.907; p = 0.029). In a comparison of the conﬁrmed
cases treated with both regimens, there was no signiﬁcant
difference in mean time to the resolution (CLR + MXF regi-
men, 15.6 ± 1.8 weeks; CLR + AMK, 20.3 ± 6.6 weeks;
p = 0.076, respectively; data not shown).
The frequencies and types of drug-related adverse events
were similar in both treatment groups. Eighteen patients
(54.5%) in the CLR + AMK regimen and 14 (73.7%) in the
CLR + MXF regimen had at least one or more drug-related
adverse events. The most frequent adverse event for both
regimens was gastrointestinal discomfort. Three patients
treated with CLR + MXF discontinued the medications
within 4 weeks of therapy due to drug-related adverse
events such as gastrointestinal discomfort and dizziness.
Discussion
This prospective observational study of patients with cutane-
ous M. abscessus infections is the ﬁrst clinical trial to com-
pare two combination antimicrobial regimens. The results
showed that a combination of clarithromycin and moxiﬂoxa-
cin resulted in more rapid resolution of the cutaneous
lesions compared with the combination of clarithromycin
and amikacin. In a comparison of the conﬁrmed cases in two
treatment regimen groups, the mean time to resolution was
longer in the group treated with clarithromycin and amikacin,
although it was not statistically signiﬁcant. In the Cox regres-
sion analysis, prior incision and drainage or excision during
the medical therapy did not inﬂuence the outcome, which is
consistent with a previous report that showed that the type
and timing of the drainage procedures did not appear to be
associated with the treatment outcome [7].
With regard to the drug-related adverse events, there
were no signiﬁcant differences in the incidence of adverse
events between the two treatment regimens, although pre-
mature discontinuation within 4 weeks occurred in six of the
patients who received a combination of clarithromycin and
moxiﬂoxacin.
According to the current recommended therapy, skin and
soft tissue infection may be successfully treated within 3–
6 months, with or without concomitant surgical debridement
[2]. The median duration of treatment was 18 weeks (range,
10–36 weeks) in our observational study; this is similar to
the recommended time in a previous study [2,16]. Villanueva
et al. [3] suggested that shorter courses (perhaps 3 months)
would be adequate for a good clinical response when surgical
TABLE 1. Baseline characteristics and follow-up data for 52
patients treated with clarithromycin plus amikacin or clari-










Age (years, mean ± SD) 50.27 ± 11.15 50.26 ± 14.11 0.098
Sex (M/F) 5/28 3/16 1.000
Clinical condition
Diabetes mellitus 1 (3.0) 2 (10.5) 0.546
Hypertension 2 (6.1) 6 (31.6) 0.40
Cancer 1 (3.0) 2 (10.5) 0.546
Classiﬁcation of cases
Conﬁrmed 7 (21.2) 9 (47.7) 0.065
Clinical 26 (78.8) 10 (52.6)
Location of lesions
Upper extremity 10 (30.3) 4 (21.1) 0.046
Lower extremity 1 (3.0) 4 (21.1)
Trunk 16 (48.5) 10 (52.6)
Upper extremity and trunk 0 1 (5.3)
Lower extremity and trunk 6 (18.2) 0
Number of lesions
Single lesion 9 (27.3) 8 (42.1) 0.360
Multiple lesions 24 (72.7) 11 (57.9)
Total number (mean ± SD) 4.61 ± 4.62 2.84 ± 2.52 0.132
Pus discharge from lesions 9 (27.3) 4 (21.1) 0.746
Prior incision and drainage
at site of infection
27 (81.8) 6 (31.6) 0.001
Follow-up experience
Change in treatment
regimen within 4 weeks
6 (18.2) 6 (31.6) 0.317
Data are no. (%) of patients, unless otherwise indicated.
CLR, clarithromycin; AMK, amikacin; MXF, moxiﬂoxacin.
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resection was performed. However, in our study, complete
resolution of cutaneous lesions within 12 weeks occurred
only in four (14.8%) and two (15.4%) patients who were
treated with clarithromycin plus amikacin and clarithromycin
plus moxiﬂoxacin, respectively. Although the optimal dura-
tion of therapy depends on the disease severity, our data
suggest that treatment for 3 months, with or without con-
comitant surgical debridement, is insufﬁcient.
The recommended antibiotic regimen includes clarithro-
mycin supplemented with other drugs, because long-term
macrolide monotherapy can induce macrolide resistance and
expression of the erm gene, which reduce the efﬁcacy of
macrolide-based treatments [1,2,12,24–26]. Amikacin is an
effective drug against M. abscessus. Due to its ototoxicity and
nephrotoxicity, monitoring of the serum concentrations of
amikacin as well as vestibular and renal function testing
should be performed during amikacin use. High-dose cefoxi-
tin (12 g/day) in combination with amikacin is recommended
for initial therapy (minimum, 2 weeks) until clinical improve-
ment [27]. However, long-term treatment with cefoxitin fre-
quently causes adverse reactions such as neutropenia and
thrombocytopenia [27–29]. Imipenem may also have some
therapeutic potential; however, its use is limited by cost and
FIG. 2. PFGE patterns of 12 isolates of M. abscessus obtained by Ase
I digestion. Lane M, lambda DNA size standard (the values on the
left are in kilobases); lanes 1–12, M. abscessus of clinical isolates from
patients. PFGE, pulsed-ﬁeld gel electrophoresis.
FIG. 3. Kaplan–Meier plots showing a comparison of duration of
medical treatment needed for resolution of cutaneous lesions in
patients treated with clarithromycin plus amikacin or clarithromycin
plus moxiﬂoxacin for cutaneous M. abscessus infections.
TABLE 2. In vitro antimicrobial susceptibility of M. abscessus isolates from culture-conﬁrmed patients (n = 12)
Patient
MIC (lg/mL)
AMK FOX CIP CLR DOX IMIa LZD* SMXb TOB* MXFc* GATc LVXc
Patient-1 4 (S) 32 (I) 4 (R) 0.25 (S) 64 (R) 8 (I) 4 (S) 64 (R) 8 (I) 4 4 8
Patient-2 4 (S) 32 (I) 4 (R) 0.25 (S) 128 (R) 8 (I) 8 (S) 128 (R) 8 (I) 4 4 8
Patient-3 4 (S) 16 (S) 2 (I) 0.25 (S) 64 (R) 4 (S) 4 (S) 128 (R) 8 (I) 1 2 4
Patient-4 4 (S) 16 (S) 2 (I) 0.25 (S) 64 (R) 4 (S) 2 (S) 128 (R) 2 (S) 1 2 4
Patient-5 4 (S) 32 (I) 2 (I) 0.25 (S) 128 (R) 8 (I) 4 (S) 64 (R) 8 (I) 4 2 4
Patient-6 4 (S) 32 (I) 4 (R) 0.25 (S) 256 (R) 16 (R) 4 (S) 128 (R) 8 (I) 4 4 8
Patient-7 4 (S) 16 (S) 1 (S) 0.25 (S) 64 (R) 2 (S) 4 (S) 64 (R) 8 (I) 4 2 4
Patient-8 4 (S) 64 (I) 4 (R) 0.25 (S) 256 (R) 4 (S) 8 (S) 128 (R) 8 (I) 8 4 8
Patient-9 4 (S) 32 (I) 2 (I) 0.25 (S) 64 (R) 4 (S) 16 (I) 64 (R) 8 (I) 8 4 8
Patient-10 4 (S) 32 (I) 2 (I) 0.125 (S) 64 (R) 4 (S) 8 (S) 128 (R) 8 (I) 8 4 8
Patient-11 4 (S) 32 (I) 2 (I) 0.25 (S) 256 (R) 4 (S) 8 (S) 128 (R) 8 (I) 4 8 8
Patient-12 4 (S) 32 (I) 4 (R) 0.25 (S) 256 (R) 8 (I) 4 (S) 128 (R) 8 (I) 4 4 8
AMK, amikacin; FOX, cefoxitin; CIP, ciproﬂoxacin; CLR, clarithromycin; DOX, doxycycline; IMI, imipenem; LZD, linezolid; SMX, sulfamethoxazole; TOB, tobramycin; MXF,
moxiﬂoxacin; GAT, gatiﬂoxacin; LVX, levoﬂoxacin; S, susceptible; I, intermediate; R, resistant.
aImipenem MICs are not reported for M. chelonae-abscessus group isolates due to lack of reproducibility.
bThe MIC endpoint is 80% inhibition of growth.
cDrugs for which CLSI breakpoints have not yet been determined against M. abscessus.
*Drugs were tested for use with the validated dry-form Sensititre panels made by Trek Diagnostic System (Westlake, OH, USA).
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the need for intravenous administration. Among the eight an-
timicrobials initially recommended for MIC testing by CLSI,
ciproﬂoxacin and doxycycline are the available oral agents.
However, previous studies [13,30] have shown that less than
5% of ciproﬂoxacin- and doxycycline-treated M. abscessus
lesions were susceptible or intermediate. Low susceptibility
of these agents has restricted their use. In our study, 91.7%
of isolates were resistant or intermediate to ciproﬂoxacin.
Therefore, ciproﬂoxacin should not be selected based on the
results of the susceptibility test.
Although there are no available data on the breakpoint of
moxiﬂoxacin for M. abscessus, moxiﬂoxacin shows activity
against M. abscessus and other rapidly growing mycobacteria
in vitro [17,31]. Recently, Cremades et al. [32] reported that
the combination of clarithromycin with moxiﬂoxacin exhib-
ited activity against M. abscessus in the stationary phase, in
spite of being nonbactericidal on its own, whereas the com-
bination of clarithromycin and amikacin was not effective
against this organism. Collectively, these ﬁndings are consis-
tent with our results.
Our study is limited by its small sample size and nonran-
domized nature. Because patients were allocated to each
treatment group depending on the availability of amikacin
injection, we cannot exclude the potential for bias. In this
study, patients received amikacin at a dose that was lower
than the recommended dosage [2], which might have caused
the longer resolution time of cutaneous lesions in the clari-
thromycin with amikacin group. As for the regimen, we refer
to a previous report in which Ryu et al. [5] found that treat-
ment with clarithromycin 250 mg twice a day and intramus-
cular injection of amikacin 250 mg three times a week was
effective in acupuncture-related M. abscessus cutaneous infec-
tion in Korea. We were also concerned about the risk of
nephrotoxicity with long-term use of amikacin because the
mean age of the patients was over 50 years. In addition, our
study was not supported by microbiological studies of the
efﬁcacy and synergy of the combination of clarithromycin
and moxiﬂoxacin.
However, it is unlikely that a randomized controlled trial
for the evaluation of this combination therapy can be per-
formed because of the low incidence and accidental occur-
rence of this infection. Therefore, data from both this
observational study of cutaneous M. abscessus infections and
antimicrobial susceptibility reports can be used to support
the appropriate regimens for the treatment of cutaneous
M. abscessus infection.
In summary, the results of this study showed that the
combination of clarithromycin and moxiﬂoxacin is associated
with a more rapid resolution of cutaneous lesions caused by
M. abscessus compared with the combination of clarithromy-
cin and amikacin. These ﬁndings support the use of moxiﬂox-
acin as an oral agent combined with clarithromycin for the
treatment of cutaneous M. abscessus infections.
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